JP2019502689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502689A5 JP2019502689A5 JP2018531325A JP2018531325A JP2019502689A5 JP 2019502689 A5 JP2019502689 A5 JP 2019502689A5 JP 2018531325 A JP2018531325 A JP 2018531325A JP 2018531325 A JP2018531325 A JP 2018531325A JP 2019502689 A5 JP2019502689 A5 JP 2019502689A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- use according
- antibody
- subject
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003815 Interleukin-11 Human genes 0.000 claims description 10
- 108090000177 Interleukin-11 Proteins 0.000 claims description 10
- 230000003827 upregulation Effects 0.000 claims description 8
- 108040006873 interleukin-11 receptor activity proteins Proteins 0.000 claims description 5
- 210000002216 heart Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 229940074383 interleukin-11 Drugs 0.000 claims 9
- 206010016654 Fibrosis Diseases 0.000 claims 8
- 230000004761 fibrosis Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 3
- 102000004553 Interleukin-11 Receptors Human genes 0.000 claims 2
- 108010017521 Interleukin-11 Receptors Proteins 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 208000031471 Macular fibrosis Diseases 0.000 claims 1
- 208000031472 Retinal fibrosis Diseases 0.000 claims 1
- 208000036038 Subretinal fibrosis Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 210000003709 heart valve Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 201000009015 preretinal fibrosis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522186.4A GB201522186D0 (en) | 2015-12-16 | 2015-12-16 | Treatment of fibrosis |
| GB1522186.4 | 2015-12-16 | ||
| PCT/EP2016/081430 WO2017103108A1 (en) | 2015-12-16 | 2016-12-16 | Treatment of fibrosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139045A Division JP7102474B2 (ja) | 2015-12-16 | 2020-08-20 | 線維化の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502689A JP2019502689A (ja) | 2019-01-31 |
| JP2019502689A5 true JP2019502689A5 (OSRAM) | 2019-10-31 |
| JP6753933B2 JP6753933B2 (ja) | 2020-09-09 |
Family
ID=55274842
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531325A Active JP6753933B2 (ja) | 2015-12-16 | 2016-12-16 | 線維化の治療 |
| JP2020139045A Active JP7102474B2 (ja) | 2015-12-16 | 2020-08-20 | 線維化の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139045A Active JP7102474B2 (ja) | 2015-12-16 | 2020-08-20 | 線維化の治療 |
Country Status (24)
| Country | Link |
|---|---|
| US (16) | US10035852B2 (OSRAM) |
| EP (7) | EP3298040B1 (OSRAM) |
| JP (2) | JP6753933B2 (OSRAM) |
| KR (2) | KR20240152973A (OSRAM) |
| CN (2) | CN108495861B (OSRAM) |
| AU (7) | AU2016369407B2 (OSRAM) |
| CA (1) | CA3007750A1 (OSRAM) |
| CY (1) | CY1120950T1 (OSRAM) |
| DK (1) | DK3298040T3 (OSRAM) |
| ES (1) | ES2692773T3 (OSRAM) |
| GB (1) | GB201522186D0 (OSRAM) |
| HR (1) | HRP20181692T1 (OSRAM) |
| HU (1) | HUE041433T2 (OSRAM) |
| LT (1) | LT3298040T (OSRAM) |
| NZ (1) | NZ744307A (OSRAM) |
| PL (1) | PL3298040T3 (OSRAM) |
| PT (1) | PT3298040T (OSRAM) |
| RS (1) | RS57894B1 (OSRAM) |
| SG (2) | SG11201804836RA (OSRAM) |
| SI (1) | SI3298040T1 (OSRAM) |
| SM (1) | SMT201800601T1 (OSRAM) |
| TR (1) | TR201815415T4 (OSRAM) |
| WO (1) | WO2017103108A1 (OSRAM) |
| ZA (1) | ZA201803727B (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| CA3045871A1 (en) * | 2016-12-16 | 2018-06-21 | Singapore Health Services Pte Ltd | Il-11 antibodies |
| GB201716733D0 (en) * | 2017-10-12 | 2017-11-29 | Nat Univ Singapore | Treatment of SMC mediated disease |
| GB201806918D0 (en) * | 2018-04-27 | 2018-06-13 | Enleofen Bio Pte Ltd | Combination treatment for eye fibrosis |
| GB201809699D0 (en) * | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| GB201809700D0 (en) * | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| AU2020211695A1 (en) * | 2019-01-21 | 2021-09-02 | National University Of Singapore | Treatment of hepatotoxicity |
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
| GB201906291D0 (en) | 2019-05-03 | 2019-06-19 | Singapore Health Serv Pte Ltd | Treatment and prevention of metabolic diseases |
| CN114364693A (zh) * | 2019-05-03 | 2022-04-15 | 新加坡保健服务私人有限公司 | 代谢性疾病的治疗和预防 |
| WO2021024170A1 (en) * | 2019-08-05 | 2021-02-11 | Voloshin Sela Tali | Increasing cancer cells' sensitivity to tumor treating fields (ttfields) by inhibiting il11 activity |
| KR102270700B1 (ko) * | 2019-11-01 | 2021-06-30 | 한국과학기술연구원 | 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용 |
| GB202009292D0 (en) | 2020-06-18 | 2020-08-05 | Singapore Health Serv Pte Ltd | Treatment and prevention of disease caused by type IV collagen dysfunction |
| CN113651888B (zh) * | 2020-08-13 | 2022-08-16 | 广东东阳光药业有限公司 | Il-11的抗体及其应用 |
| GB202017244D0 (en) | 2020-10-30 | 2020-12-16 | Nat Univ Singapore | Methods to extend health-span and treat age-related diseases |
| CA3211686A1 (en) | 2021-02-26 | 2022-09-01 | Bayer Aktiengesellschaft | Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding |
| JP2024526944A (ja) | 2021-07-26 | 2024-07-19 | ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー | アルコール性肝疾患の処置および予防 |
| WO2023034809A1 (en) | 2021-08-30 | 2023-03-09 | Lassen Therapeutics 1, Inc. | Anti-il-11rα antibodies |
| CN115068442A (zh) * | 2021-09-13 | 2022-09-20 | 荣灿生物医药技术(上海)有限公司 | 核酸的纳米颗粒组合物、其制备方法和用途 |
| EP4448096A1 (en) | 2021-12-16 | 2024-10-23 | Singapore Health Services Pte. Ltd. | Treatment and prevention of glomerular disease |
| CN115414346B (zh) * | 2022-08-29 | 2023-09-29 | 湖南复瑞生物医药技术有限责任公司 | 一种应用胺碘酮构造肺纤维化模型的方法 |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| WO2024225979A1 (en) | 2023-04-25 | 2024-10-31 | Vvb Bio Pte Ltd | Anti il-11 antibody |
| CN120518762B (zh) * | 2023-06-05 | 2025-12-26 | 北京东方百泰生物科技股份有限公司 | 一种结合il-11的抗体、其抗原结合片段及应用 |
| GB202311050D0 (en) | 2023-07-19 | 2023-08-30 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| CN117085137A (zh) * | 2023-10-10 | 2023-11-21 | 上海交通大学医学院附属第九人民医院 | Il-11抑制剂及其在抗瘢痕治疗中的应用 |
| CN117964734B (zh) * | 2024-03-04 | 2025-12-26 | 四川大学 | 一种重组人白介素-11突变体及其与化学分子偶联缀合物和其制备方法与应用 |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
| GB202408044D0 (en) | 2024-06-06 | 2024-07-24 | Vvb Bio Pte Ltd | gp130 antigen-binding molecules |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
| ATE342970T1 (de) | 1994-12-22 | 2006-11-15 | Genetics Inst Llc | Verwendung eines menschlichen interleukin-11 rezeptors |
| ES2093562B1 (es) | 1995-05-26 | 1997-07-01 | Univ Santiago Compostela | Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. |
| US5679339A (en) | 1995-06-27 | 1997-10-21 | Keith; James | Method of using IL-11 for treating spondyloarthropies |
| US6540993B1 (en) | 1995-06-27 | 2003-04-01 | Wyeth | Method of treating inflammatory bowel disease using a topical formulation of IL-11 |
| US6126933A (en) | 1995-06-27 | 2000-10-03 | Genetics Institute | Methods of treating inflammatory bowel diseases by administering IL-11 |
| US6649192B2 (en) | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
| GB9702944D0 (en) * | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
| GB9721961D0 (en) | 1997-10-16 | 1997-12-17 | Glaxo Group Ltd | Novel molecules |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CA2237915A1 (en) | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
| US6953777B2 (en) | 1999-03-11 | 2005-10-11 | Genetics Indtitute LLC | Use of interleukin-11 to prevent immune-mediated cytotoxicity |
| WO2000078336A1 (en) * | 1999-06-21 | 2000-12-28 | Genetics Institute, Inc. | Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB0021668D0 (en) | 2000-09-04 | 2000-10-18 | Smithkline Beecham Plc | New use |
| AU2002362088A1 (en) | 2001-12-06 | 2003-06-23 | Catholic University | Method and composition for inducing weight loss |
| CN1688293A (zh) | 2002-09-16 | 2005-10-26 | 韦思公司 | 多肽治疗剂口服给药的缓释配方及其使用方法 |
| WO2005058956A1 (en) | 2003-12-16 | 2005-06-30 | Commonwealth Scientific And Industrial Research Organisation | Cytokine binding domains |
| US20060019890A1 (en) | 2004-01-15 | 2006-01-26 | Kapoun Ann M | Method for treating cardiac remodeling following myocardial injury |
| WO2005098041A2 (en) | 2004-03-26 | 2005-10-20 | University Of Florida Research Foundation, Inc. | Detection and treatment of fibrotic disorders |
| EP1630232B1 (en) | 2004-08-27 | 2008-07-02 | CONARIS research institute AG | Optimized nucleotide sequences encoding sgp130 |
| EP1957097A1 (en) | 2005-12-06 | 2008-08-20 | Wyeth a Corporation of the State of Delaware | Interleukin-11 compositions and methods of use |
| MX352516B (es) | 2006-07-05 | 2017-04-06 | Fibrotech Therapeutics Pty Ltd | Compuestos terapeuticos. |
| US8361966B2 (en) | 2006-10-27 | 2013-01-29 | Osaka University | Use of interleukin-11 as therapeutic agent for heart disease |
| US20100239570A1 (en) * | 2007-09-13 | 2010-09-23 | Roger Nitsch | Moncolonal amyloid beta (abeta) - specific antibody and uses thereof |
| WO2009052588A1 (en) | 2007-10-26 | 2009-04-30 | Csl Limited | Cytokine muteins |
| US8182814B2 (en) | 2007-10-26 | 2012-05-22 | Csl Limited | Methods of treating inflammatory airway conditions by inhibition of IL-11 activity |
| US8518888B2 (en) | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| KR101133769B1 (ko) | 2011-04-18 | 2012-04-09 | 한국생명공학연구원 | 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 |
| KR102489953B1 (ko) | 2013-02-07 | 2023-01-20 | 씨에스엘 리미티드 | Il-11r 결합 단백질 및 이의 용도 |
| CN105497893B (zh) | 2015-12-10 | 2019-02-01 | 黑龙江省科学院高技术研究院 | IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用 |
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| RU2016125115A (ru) | 2016-06-23 | 2017-12-28 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов |
| GB201621431D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore The | Decoy cytokine receptor |
| CA3045871A1 (en) | 2016-12-16 | 2018-06-21 | Singapore Health Services Pte Ltd | Il-11 antibodies |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| RU2016151730A (ru) | 2016-12-28 | 2018-06-29 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Антитела для лабораторной диагностики концентрации интерлейкина-11 |
| GB201716733D0 (en) | 2017-10-12 | 2017-11-29 | Nat Univ Singapore | Treatment of SMC mediated disease |
| NL2020093B1 (en) | 2017-12-15 | 2019-06-25 | Stahl Int B V | Process for producing aqueous polyurethane dispersions in a continuous manner; apparatus suitable for performing such a process; and products obtained by said process |
| GB201806918D0 (en) | 2018-04-27 | 2018-06-13 | Enleofen Bio Pte Ltd | Combination treatment for eye fibrosis |
| GB201809699D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| GB201809700D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
-
2015
- 2015-12-16 GB GBGB1522186.4A patent/GB201522186D0/en not_active Ceased
-
2016
- 2016-12-16 JP JP2018531325A patent/JP6753933B2/ja active Active
- 2016-12-16 NZ NZ744307A patent/NZ744307A/en unknown
- 2016-12-16 EP EP16822941.7A patent/EP3298040B1/en not_active Revoked
- 2016-12-16 EP EP18185321.9A patent/EP3428187A1/en not_active Withdrawn
- 2016-12-16 PT PT16822941T patent/PT3298040T/pt unknown
- 2016-12-16 EP EP18185326.8A patent/EP3428188A1/en not_active Withdrawn
- 2016-12-16 CN CN201680074600.XA patent/CN108495861B/zh active Active
- 2016-12-16 SM SM20180601T patent/SMT201800601T1/it unknown
- 2016-12-16 US US15/381,622 patent/US10035852B2/en active Active
- 2016-12-16 EP EP18185323.5A patent/EP3431498A1/en not_active Withdrawn
- 2016-12-16 HR HRP20181692TT patent/HRP20181692T1/hr unknown
- 2016-12-16 AU AU2016369407A patent/AU2016369407B2/en active Active
- 2016-12-16 EP EP18176010.9A patent/EP3428186A1/en active Pending
- 2016-12-16 HU HUE16822941A patent/HUE041433T2/hu unknown
- 2016-12-16 WO PCT/EP2016/081430 patent/WO2017103108A1/en not_active Ceased
- 2016-12-16 SG SG11201804836RA patent/SG11201804836RA/en unknown
- 2016-12-16 KR KR1020247034233A patent/KR20240152973A/ko active Pending
- 2016-12-16 LT LTEP16822941.7T patent/LT3298040T/lt unknown
- 2016-12-16 RS RS20181140A patent/RS57894B1/sr unknown
- 2016-12-16 DK DK16822941.7T patent/DK3298040T3/en active
- 2016-12-16 SI SI201630104T patent/SI3298040T1/sl unknown
- 2016-12-16 ES ES16822941T patent/ES2692773T3/es active Active
- 2016-12-16 TR TR2018/15415T patent/TR201815415T4/tr unknown
- 2016-12-16 EP EP18188951.0A patent/EP3431500A1/en not_active Withdrawn
- 2016-12-16 EP EP18188947.8A patent/EP3431499A1/en not_active Withdrawn
- 2016-12-16 KR KR1020187020275A patent/KR102720360B1/ko active Active
- 2016-12-16 SG SG10201908380T patent/SG10201908380TA/en unknown
- 2016-12-16 PL PL16822941T patent/PL3298040T3/pl unknown
- 2016-12-16 CA CA3007750A patent/CA3007750A1/en active Pending
- 2016-12-16 CN CN202310056618.9A patent/CN116036284A/zh active Pending
-
2018
- 2018-05-24 US US15/988,463 patent/US10106603B2/en active Active
- 2018-06-05 ZA ZA2018/03727A patent/ZA201803727B/en unknown
- 2018-08-06 US US16/055,283 patent/US10894826B2/en active Active
- 2018-08-06 US US16/055,245 patent/US10870696B2/en active Active
- 2018-08-06 US US16/055,251 patent/US10870697B2/en active Active
- 2018-08-06 US US16/055,319 patent/US10894827B2/en active Active
- 2018-08-06 US US16/055,270 patent/US10894825B2/en active Active
- 2018-08-06 US US16/055,261 patent/US10865239B2/en active Active
- 2018-08-06 US US16/055,304 patent/US10822405B2/en active Active
- 2018-08-06 US US16/055,295 patent/US10927169B2/en active Active
- 2018-08-21 US US16/106,050 patent/US10899832B2/en active Active
- 2018-08-21 US US16/106,047 patent/US10889642B2/en active Active
- 2018-08-21 US US16/106,044 patent/US10865241B2/en active Active
- 2018-08-21 US US16/106,041 patent/US10865240B2/en active Active
- 2018-09-13 AU AU2018229484A patent/AU2018229484B9/en active Active
- 2018-09-13 AU AU2018229482A patent/AU2018229482B2/en active Active
- 2018-09-13 AU AU2018229483A patent/AU2018229483B2/en active Active
- 2018-09-13 AU AU2018229487A patent/AU2018229487B2/en active Active
- 2018-09-13 AU AU2018229485A patent/AU2018229485B2/en active Active
- 2018-09-13 AU AU2018229486A patent/AU2018229486B2/en active Active
- 2018-10-31 CY CY181101130T patent/CY1120950T1/el unknown
-
2020
- 2020-08-20 JP JP2020139045A patent/JP7102474B2/ja active Active
- 2020-12-02 US US17/110,094 patent/US11939374B2/en active Active
-
2024
- 2024-02-08 US US18/436,088 patent/US20240360211A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| MX390722B (es) | Tratamiento de resistencia a diureticos. | |
| EP3941551A4 (en) | SUBCUTANEOUS ADMINISTRATION OF NANOPARTICLES WITH AN MTOR INHIBITOR AND ALBUMIN FOR THE TREATMENT OF DISEASES | |
| Gunal | How to determine ‘dry weight’? | |
| Honore et al. | The big bang of hemofiltration: the beginning of a new era in the third millennium for extra-corporeal blood purification! | |
| MX2019006141A (es) | Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes. | |
| MA39294A1 (fr) | Polythérapie contre le cancer | |
| Abraham et al. | Management of hypertension in chronic kidney disease: consensus statement by an expert panel of Indian nephrologists | |
| HRP20220470T4 (hr) | Uporaba landiolol hidroklorida u dugotrajnom liječenju tahiaritmija | |
| EP3781688A4 (en) | TNF APTAMERS AND USES FOR THE TREATMENT OR DIAGNOSIS OF TNF RELATED INFLAMMATORY DISEASES | |
| MX2021003798A (es) | Terapia con celulas de placenta humana y celulas hematopoyeticas. | |
| WO2019055776A3 (en) | Compositions and methods for treatment of diseases involving cxcl1 function | |
| ZA202006986B (en) | Dantrolene formulations and methods of their use | |
| Nalley | Debate: What Role Do Transplants Play in the Treatment of Myeloma? | |
| Iwashima et al. | CIRCADIAN HAEMODYNAMIC CHARACTERISTICS IN PATIENTS WITH PRIMARY ALDOSTERONISM | |
| Bica et al. | 428 BONE MARROW MONONUCLEAR CELLS THERAPY IMPROVES LIVER PERFUSION IN CIRRHOTIC PATIENTS | |
| Lanspa et al. | Utility Of Central Venous Pressure And Shock Index In Predicting Hemodynamic Response To Fluid Challenge In Patients With Septic Shock | |
| 余德毅 et al. | Preliminary outcome of free flap monitoring by laser Doppler imager | |
| Runolfsdottir | Blurred vision, punctate keratitis and ocular dryness: 2 case reports | |
| UA94691U (uk) | Спосіб оцінки ефективності лікування ніацином хворих на ішемічну хворобу серця з стенокардією та артеріальною гіпертензією з порушенням діастолічної функції лівого шлуночка по "гіпертрофічному" типу | |
| Wu et al. | Effect of N-acetylcysteine on cardiac function and myocardial energy metabolism of heart failure rabbits | |
| Fakhraddeen Muhammad MBBS et al. | PREVALENCE AND DETERMINANTS OF METABOLIC SYNDROME AMONG HIV INFECTED PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN KANO, NORTHWESTERN NIGERIA | |
| Terabe et al. | SAT0013 Risk Factors for Progression of Large Joint Destruction in Patients with Rheumatoid Arthritis Based on Incident Rate of Joint Surgery During Treatment with Biologics | |
| JP2014240383A5 (OSRAM) | ||
| Schullo-Feulner | Enoxaparin sodium/warfarin |